# Theriva Biologics, Inc.: overview TOVX · NYSE · CIK 894158 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/tovx.md) · [Financials](/companies/tovx/financials.md) · [Filings](/companies/tovx/filings.md) · [Insiders](/companies/tovx/insiders.md) Latest reported revenue: [$0](/filings/0001104659-26-093786.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001104659-26-093786). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | [300](/filings/0001104659-26-055689.md) | [0.0 d](/filings/0001104659-26-093786.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | [(709.0%)](/filings/0001104659-26-055689.md) | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | [(681.3%)](/filings/0001104659-26-093786.md) | not reported | | Diluted EPS | $ per share | [(6.81)](/filings/0001104659-25-109828.md) | not reported | [(1.55)](/filings/0001104659-26-055689.md) | [(1.93)](/filings/0001104659-26-093786.md) | [(0.45)](/filings/0001104659-25-109828.md) | not reported | [(0.05)](/filings/0001104659-26-055689.md) | [(0.07)](/filings/0001104659-26-093786.md) | | Free cash flow | $k | [(3,913) d](/filings/0001104659-25-109828.md) | [(4,691) d](/filings/0001104659-26-026767.md) | not reported | not reported | [(4,338) d](/filings/0001104659-25-109828.md) | [(2,882) d](/filings/0001104659-26-026767.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 6-month figure less the 3-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 6-month figure less the 3-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.90)](/filings/0001410578-23-000428.md) | [(1.31)](/filings/0001410578-24-000293.md) | [(28.48)](/filings/0001410578-25-000285.md) | [(19.03)](/filings/0001104659-26-026767.md) | [(2.08)](/filings/0001104659-26-026767.md) | | Free cash flow | $m | [(12.9)](/filings/0001410578-23-000428.md) | [(19.2)](/filings/0001410578-24-000293.md) | [(19.2)](/filings/0001410578-25-000285.md) | [(16.9)](/filings/0001104659-26-026767.md) | [(16.7)](/filings/0001104659-26-026767.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Net income: us-gaap:ProfitLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/tovx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $121.5k | 486,179 | | Added +293,775 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $83.0k | 331,922 | | Added +154,888 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $73.6k | 294,021 | | Reduced −156,242 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $60.4k | 241,780 | | Unchanged | | [Ikarian Capital, LLC](/funds/1778253.md) | 2026-06-30 | $28.0k | 112,076 | | Unchanged | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $20.7k | 82,700 | | New +82,700 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $15.9k | 63,710 | | New +63,710 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $15.3k | 61,053 | | Reduced −164,571 | | [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $13.5k | 53,868 | | Reduced −40,752 | | [Ground Swell Capital, LLC](/funds/1534450.md) | 2026-06-30 | $8.8k | 35,292 | | New +35,292 | ## Recent filings [All 806 filings](/companies/tovx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-20 | 20:15 ET | [DEF 14A](/filings/0001104659-26-117417.md) | Proxy statement, period 2026-11-18 | 0001104659-26-117417 | | 2026-08-11 | 12:16 ET | [10-Q](/filings/0001104659-26-093786.md) | Quarterly report, period 2026-06-30 | 0001104659-26-093786 | | 2026-08-11 | 12:10 ET | [8-K](/filings/0001104659-26-093782.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-093782 | | 2026-08-06 | 12:10 ET | [8-K](/filings/0001104659-26-091674.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-091674 | | 2026-08-04 | 11:20 ET | [8-K](/filings/0001104659-26-090064.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-090064 | | 2026-07-07 | 12:10 ET | [8-K](/filings/0001104659-26-080962.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-080962 | | 2026-06-29 | 21:28 ET | [DEF 14A](/filings/0001104659-26-078859.md) | Proxy statement, period 2026-08-03 | 0001104659-26-078859 | | 2026-06-11 | 12:10 ET | [8-K](/filings/0001104659-26-072633.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-072633 | | 2026-06-05 | 20:05 ET | [8-K](/filings/0001104659-26-070966.md) | 8.01 Other events | 0001104659-26-070966 | | 2026-05-05 | 20:41 ET | [10-Q](/filings/0001104659-26-055689.md) | Quarterly report, period 2026-03-31 | 0001104659-26-055689 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-026767.md), filed Mar 12, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/9e811919-15af-41e5-b40a-b3939c85cff3) ## About the filer - CIK: 894158 - Tickers: TOVX - Exchange: NYSE - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.